#AHA22 LBCTs one liners:
1. TRANSFORM-HF: Torsemide was not superior to furosemide in improving survival among patients treated for decompensated HF.
2. DCP: No differences in cardiovascular outcomes between chlorthalidone and HCTZ among elderly veterans with HTN.
"Empagliflozin now has FDA approval for reducing cardiovascular death or hospitalization among patients with heart failure with preserved left ventricular ejection fraction, defined as more than 40%, with or without diabete"
https://t.co/ITIt3a4j4Z
As a cardiologist, I frequently get questions about aspirin. So I’ve summarized a list of FAQs with my answers below.
(As always, this is not individual medical advice. Please consult with your doctor).
Feel free to add to this and share. Okay, here we go! 🧵…
ACC Releases Clinical Guidance on Cardiovascular Consequences of COVID-19 in Adults. The🆕Expert Consensus Decision Pathway provides a framework for understanding, evaluating & managing CV sequelae of #COVID19. #CardioTwitter
🧵Key Points 👇 (1/8)
In Italy last week, data reported that 20% of health-care workers responding to #COVID19 were infected, and some have died. Editorial outlines the urgent imperative to protect health-care workers https://t.co/BbS8sJZ8G0
No contexto da actual pandemia e até indicação em contrário os EssentialCourses encontram-se suspensos por tempo indeterminado!! Um por todos, todos por um! A maior fortuna para quem está nas “trincheiras”
In Press: Impact of creatinine clearance on clinical outcomes in elderly atrial fibrillation patients receiving apixaban: J-ELD AF registry sub-analysis. https://t.co/h5EyhlPoLg
Evolocumab shows long-term safety and efficacy in plasama LDL-C level reduction over a median 4.1 years in severe familial hypercholesterolemia patients. How will this impact your practice? https://t.co/q8CPu8VFID #JACC@rauldsf_santos